Ibnsina PharmaCAI:ISPH 85 FCF Yield % is 6.98 as of Jul. 06, 2026. GuruFocus rates CAI:ISPH with a GF Score™ of 85/100 and a GF Value™ of E£10.49 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 116 Medical Distribution companies, Ibnsina Pharma ranks better than 67.24% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Ibnsina Pharma FCF Yield % Related Terms
Ibnsina Pharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ibnsina Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma FCF Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a FCF Yield % of 6.98 as of Jul. 06, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Ibnsina Pharma and its competitors. According to the industry distribution chart, Ibnsina Pharma ranks #38 out of 116 companies in the Medical Distribution industry, placing it in the top 32.8%.
Is Ibnsina Pharma's FCF Yield % too high?
Ibnsina Pharma's current FCF Yield % is 6.98. The Medical Distribution industry median FCF Yield % is 2.44. Ibnsina Pharma's value of 6.98 is 186.7% above this industry median. Based on the distribution chart, Ibnsina Pharma ranks #38 out of 116 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ibnsina Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's FCF Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #38 out of 116 companies for FCF Yield %. This puts Ibnsina Pharma in the upper half of its industry. The industry median FCF Yield % is 2.44. Ibnsina Pharma's value of 6.98 is 186.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Distribution company?
The median FCF Yield % among Medical Distribution companies is 2.44, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current FCF Yield % of 6.98 is 186.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median FCF Yield % is 2.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current FCF Yield % is 6.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.49, compared to a current price of E£11.60 — trading 10.6% above its estimated fair value. The current FCF Yield % is 6.98 and 186.7% above the Medical Distribution industry median of 2.44. Ibnsina Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current FCF Yield % is 6.98 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.60 is trading 10.6% above its estimated GF Value™ of E£10.49.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
FCF Yield %: 6.98
GF Value™: E£10.49 vs. price of E£11.60 (10.6% above fair value)
Industry Position: 186.7% above the Medical Distribution median (#38 of 116)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score
Get the complete analysis for CAI:ISPH
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
